Anthracyclines:: is more, better and/or more dangerous?

[1] Abe O, 1998, LANCET, V352, P930

[2] Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors:: 5-year follow-up results of French adjuvant study group 05 randomized trial [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) : 602 - 611

[3] Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (01) : 39 - 46

[4] Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen [J]. ANNALS OF ONCOLOGY, 2002, 13 (09) : 1378 - 1386

[5] COMPETING RISKS DETERMINING EVENT-FREE SURVIVAL IN EARLY BREAST-CANCER [J]. BRITISH JOURNAL OF CANCER, 1992, 66 (05) : 951 - 957

[6] ADJUVANT CHEMOTHERAPY IN EARLY BREAST-CANCER AND INCIDENCE OF NEW PRIMARY MALIGNANCIES [J]. LANCET, 1991, 338 (8766) : 535 - 538

[7] NONLYMPHOMATOUS MALIGNANT TUMORS COMPLICATING HODGKINS-DISEASE - POSSIBLE ASSOCIATION WITH INTENSIVE THERAPY [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1972, 287 (22) : 1119 - +

[8] Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients [J]. ANNALS OF ONCOLOGY, 2003, 14 (05) : 693 - 698

[9] Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (15) : 2836 - 2842

[10] Clarke M, 1998, LANCET, V351, P1451

[1] Abe O, 1998, LANCET, V352, P930

[2] Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors:: 5-year follow-up results of French adjuvant study group 05 randomized trial [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) : 602 - 611

[3] Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (01) : 39 - 46

[4] Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen [J]. ANNALS OF ONCOLOGY, 2002, 13 (09) : 1378 - 1386

[5] COMPETING RISKS DETERMINING EVENT-FREE SURVIVAL IN EARLY BREAST-CANCER [J]. BRITISH JOURNAL OF CANCER, 1992, 66 (05) : 951 - 957

[6] ADJUVANT CHEMOTHERAPY IN EARLY BREAST-CANCER AND INCIDENCE OF NEW PRIMARY MALIGNANCIES [J]. LANCET, 1991, 338 (8766) : 535 - 538

[7] NONLYMPHOMATOUS MALIGNANT TUMORS COMPLICATING HODGKINS-DISEASE - POSSIBLE ASSOCIATION WITH INTENSIVE THERAPY [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1972, 287 (22) : 1119 - +

[8] Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients [J]. ANNALS OF ONCOLOGY, 2003, 14 (05) : 693 - 698

[9] Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (15) : 2836 - 2842

[10] Clarke M, 1998, LANCET, V351, P1451